Calgary, Canada, November 29 (ots/PRNewswire) -
- ApoA-I Technology is Recognized for its Ability to Transform the
Treatment of Cardiovascular Disease
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce
today that the World Economic Forum has selected Resverlogix as a
winner of the very prestigious Technology Pioneer Award in
recognition of its NexVas(TM) Plaque Removal program. Candidates for
this award must be involved in the development of life-changing
technologies and have potential for long-term impact on business and
"We are elated to receive this high-level recognition from such an
important leading global body as the World Economic Forum. This
awareness that our innovative technology could have such a dramatic
positive impact for society, as it relates to the future treatment of
cardiovascular disease (CVD), further validates the positive
direction of our NexVas technology," stated Mr. Donald McCaffrey,
President, CEO & Co-Founder of Resverlogix.
Resverlogix was selected because it is developing exceptionally
promising new molecules that increase the production of ApoA-l and
high density lipoprotein (HDL) for the treatment of atherosclerosis.
According to the World Health Organization, CVD is the number one
cause of death globally, an immense problem currently responsible for
killing nearly 18 million people annually worldwide.
"I would like to offer Canada's sincere congratulations to
Resverlogix for winning this international award from the World
Economic Forum," said the Honourable Minister Jim Prentice, Minister
of Industry. "Resverlogix is doing some incredible work in advancing
the treatment of atherosclerosis, the major underlying cause of
cardiovascular disease and this award is a testament to Canada's
world-class biopharmaceutical industry."
Dr. Norman Wong, M.D., Co-Founder of Resverlogix added, "Current
therapies have made significant strides in improving outcomes but are
only able to address 30 percent of the risk associated with CVD.
Consequently there exists a significant unmet medical need for a
therapy to address the remaining 70 percent of risk. The proven
ability of our drug to increase the production of ApoA-I and
functional HDL, offers enormous potential to address this critical
unmet need and impact the leading killer in the world".
The Technology Pioneers 2008 were nominated by the world's leading
venture capital and technology companies. The final selection from
273 nominees was made by a panel of leading technology experts
appointed by the World Economic Forum. To be selected as a Technology
Pioneer, a company must be involved in the development of
life-changing technology innovation and have potential for long-term
impact on business and society. In addition, it must demonstrate
visionary leadership, show the signs of being a long-standing market
leader - and its technology must be proven. The award winners are
companies that have been identified as developing and applying highly
transformational and innovative technologies in the areas of energy,
biotechnology and health, and information technology. Previous
Technology Pioneers have included Business Objects, Gilead Sciences,
Corel Corporation, Encore Software, Google, Mozilla Corporation and
Only one of the Technology Pioneers 2008 is based in Canada while
23 companies are US-based. Israel and Switzerland each boast three;
the United Kingdom and Sweden two each; and France, Germany, India,
the Netherlands and Russia, one each. Technology Pioneers are
nominated in three main categories: Biotechnology/Health
Energy/Environment, and Information Technology.
"This year the World Economic Forum received a record number of
applications from companies around the world to become a Technology
Pioneer. From a highly competitive field, we are extremely pleased to
have a community that is using innovation and technology to
dramatically affect the way society and business operate and doing so
in a markedly collaborative manner. We are excited to welcome the
Technology Pioneers class of 2008 to the larger community of the
World Economic Forum and we are looking forward to the fruits that
their collaboration will bring," said Peter Torreele, Managing
Director of the World Economic Forum.
The entire list of Technology Pioneers and interviews with the
CEOs of the selected companies can be found here:
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition
characterized by dysfunction of the heart and blood vessels. CVD
includes atherosclerosis (especially coronary heart disease which can
lead to heart attacks), cerebrovascular disease (stroke), and
hypertension (high blood pressure). The underlying cause of most CVD
is a gradual clogging of the arteries (atherosclerosis) that supply
blood to the heart, brain and other vital organs.
The American Heart Association estimates that almost 80 million
American Adults have one or more types of cardiovascular disease. CVD
remains the number one killer of developed nations. Nearly 2,400
Americans die each day from cardiovascular disease - that is 1 person
will die every 36 seconds.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e.
transport of peripheral cholesterol including that of the vessel wall
to the liver for processing. In multiple human and animal studies
over-expression or repeated infusion of ApoA-I inhibit progression
and induce regression of atherosclerosis in animals and humans.
About the World Economic Forum
The World Economic Forum is an independent international
organization committed to improving the state of the world by
engaging leaders in partnerships to shape global, regional and
Incorporated as a foundation in 1971, and based in Geneva,
Switzerland, the World Economic Forum is impartial and
not-for-profit; it is tied to no political, partisan or national
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.
Notes to Editors:
- Go to http://www.weforum.org/techpioneers/2008 for the entire
list of Technology Pioneers and interviews with the CEOs of the
- Download print-quality high resolution photographs of the CEOs
of the selected companies at:
ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.ch
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-403-473-5359, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com